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Abstract
Introduction
The number of children with autism spectrum disorder (ASD) is rising, along with the potential for
challenging behaviors during health care encounters.

Method
We present an overview of the emerging science related to ASD diagnosis and interventions for
children with ASD.

Results
Emerging science on ASD reveals common associated challenging behaviors, increasing prevalence,
emphasis on early diagnosis at 18 to 24 months of age, changes in the diagnostic process with criteria
from the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, and interventions with
medication, education, and behavior management.

Discussion
Family and health care provider preparation strategies facilitate care of children with ASD and their
families. Early diagnosis at 18 to 24 months of age and evidence-based interventions contribute to best
outcomes for children and families. Health care providers must be aware of the state of the science for
diagnosis and best practices to provide family-centered care for this growing population.
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Autism spectrum disorder (ASD) is a developmental disorder that presents with atypical language and
social behavior, along with restrictive and repetitive behaviors and unusual interests (American
Psychiatric Association [APA], 2013). The spectrum of behaviors and their severity are highly variable
(Hall, 2012). The behaviors may be self-inflicted (e.g., hitting or biting oneself) and/or externalized
(e.g., hitting or kicking others; Johnson, Bekhet, Robinson, & Rodriguez, 2014; Matson et al., 2011).
Behaviors may be exacerbated when children are stressed, such as in health care settings (Hall, 2012,
Johnson and Rodriguez, 2013, Johnson et al., 2014, Matson et al., 2011).
Discerning the most accurate information about ASD to use as a basis for recommendations for familycentered ASD treatment can be challenging for nurse practitioners and other health care practitioners
(HCPs), given the complexity of the symptoms and wide range of presentation (Lounds Taylor et al.,
2012, Warren et al., 2011). The objective of this review article is to describe the evidence for the HCP's
role in screening, the diagnostic process, and interventions with children who have ASD. We present
background on the current state of the science related to ASD definition, associated behaviors,
prevalence, the diagnostic process, and interventions.

ASD Definition
The definition of ASD has developed over time since it was introduced in the third edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-III; American Psychiatric Association [APA],
1980). Prior to 1980, ASD symptoms were considered to be representative of early onset schizophrenia
(American Psychiatric Association, 1952, American Psychiatric Association, 1968). The fourth revision of
the DSM categorized the symptoms of ASD into three distinct pervasive developmental disorders
(PDDs): autism, PPD–not otherwise specified, and Asperger syndrome (APA, 1994). The classification of
the PDDs did not change with the DSM IV–text revision (APA, 2000). With the fifth edition of the DSM,
the three PDDs are collapsed into one diagnostic disorder, ASD. The diagnosis of Asperger syndrome
and PDD–not otherwise specified are no longer given in the DSM-5. Future prevalence studies may be
affected, given the change in the categorization of ASD with the DSM-5 (Swineford, Thurm, Baird,
Wetherby, & Swedo, 2014).
The new DSM-5 diagnostic disorder ASD has two main criteria: (A) persistent social communication
and social interaction deficits and (B) restricted, repetitive patterns of behavior, interests, or activities
(see Box 1). A child may demonstrate all of the A criteria as early as age 2 years if the child does not
respond to his or her name, has no or limited joint attention, and shows a lack of reciprocal interaction.
An example of the B criteria in a toddler is an unusually strong interest in a play telephone during
which time he does not engage with his mother, respond to his name, or share enjoyment with his
mother about the phone. Adherence to restricted routines can lead to difficulties with transitions and
challenging behaviors, such as tantrums (Weitlauf et al., 2014).
Box 1
Criteria for diagnosis of autism spectrum disordera
Criteria A: Persistent social communication and social interaction deficits in multiple contexts.
Includes deficits in all three areas:
• Social-emotional reciprocity.
• Nonverbal communicative behaviors used for social interaction.
• Developing, maintaining, and understanding relationships.
Criteria B: Restricted, repetitive patterns of behavior, interests, or activities. Includes at least
two:
• Stereotyped or repetitive movements, use of objects, or speech.
• Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal
or nonverbal behavior.
• Highly restricted, fixated interests that are abnormal in intensity or focus.
• Hyper- or hyporeactivity to sensory input or unusual sensory environment interest.
Criteria C: Symptoms were present in early developmental period.
Criteria D: Symptoms correlate with clinically significant impairments in social or occupational
functioning.
Criteria E: Impairments are not better explained by intellectual disability or global
developmental delay.
Clinician specifies the following:
• With or without intellectual impairment.

• With or without language impairment.
• Any associated or known medical or genetic condition.
• Any associated neurodevelopmental, mental or behavioral disorder.
Severity rating:
Level 1: Requires support.
Level 2: Requires substantial support.
Level 3: Requires very substantial support.
Note. aAdapted criteria for Autism Spectrum Disorder in the Diagnostic and Statistical Manual
for Mental Disorders, edition 5 (American Psychiatric Association, 2013).
The DSM-5 also requires clinicians to specify other diagnoses that may be present, such as cognitive or
language impairment, known medical or genetic conditions, and other neurodevelopmental or
behavior disorders (APA, 2013). The clinician rates the severity of the ASD on three levels. Level 1
requires support; level 2 requires substantial support; and level 3 requires very substantial support
(APA, 2013).

Associated Behaviors
Challenging behaviors that accompany ASD are sometimes very difficult for families to manage. A
variety of behaviors are associated with ASD. For example, aggression and self-injury have a significant
impact on quality of life for children and families on the autism spectrum (Johnson, Frenn, Feetham, &
Simpson, 2011). Anxiety is often seen to be a trigger for these behaviors (Davis et al., 2011). The
anxiety can be linked to both receptive and expressive communication skill deficits that accompany
ASD (Davis et al., 2010). Children with ASD also may have obsessive-compulsive features or the need
for predictability and sameness. These characteristics can lead to some stressful situations for families
(Miles, 2011).

Prevalence of ASD
Based on DSM-IV criteria, the prevalence of ASD in the United States is estimated to have increased
from 1 in 10,000 people in the 1990s (Rutter, 2007) to 1 in 68 people (about 4.7 million) in 2014, with a
4:1 male to female prevalence (Baio et al., 2014). The broadening of the concept of autism in the DSMIV to include Asperger syndrome increased the supports for ASD and the diagnostic surveillance in
health and educational care. It also improved ASD awareness, which helps explain the increasing ASD
prevalence (Baio et al., 2014, Fombonne, 2009, Rutter, 2007).
Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent
basis, which complicates the HCP's ability to recognize the earliest signs of ASD.
Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent basis,
which complicates the HCP's ability to recognize the earliest signs of ASD. This subtlety can add
another layer of diagnostic uncertainty for the clinician working with the culturally diverse child.
Although the ASD phenotype (i.e., how the child looks and behaves) does not differ by culture, the
prevalence of ASD among diverse cultural groups differs significantly. White children have a 30%

greater prevalence for being diagnosed with ASD than African American children and a 50% greater
prevalence than Hispanic children (Baio et al., 2014).
African American and Hispanic children are diagnosed with ASD on average 2.5 to 2.6 years later than
White children (Kerfeld et al., 2011, Mandell et al., 2002, Mandell et al., 2009, Valicenti-McDermott
et al., 2012). When African American and Hispanic children are diagnosed later, their ASD symptoms
can be more severe, including poorer social reciprocity or the risk for an intellectual disability (Baio
et al., 2014, Jarquin et al., 2011). Additionally, African American children with ASD are more often
misdiagnosed with a behavioral disorder such as attention deficit hyperactivity disorder, adjustment
disorder, or conduct disorder than are White children (Mandell, Ittenbach, Levy, & Pinto-Martin, 2007).
Lags in obtaining the ASD diagnoses for African American and Hispanic children can lead to preventable
delays in implementing interventions to improve outcomes (Burkett, Morris, Manning-Courtney,
Anthony, & Shambley-Ebron, 2015). These preventable delays represent a health care disparity in the
United States. Multiple cultural factors contribute to lack of early diagnosis and lack of timely
interventions for African American and Hispanic children with ASD, including (a) HCP diagnostic bias of
the White male child, whose prevalence of diagnosis with ASD is typically higher than that of other
ethnicities; (b) poorer health care accessibility than White children; (c) uncertainties about the
presenting symptoms of African American and Hispanic children; and (d) family understanding of ASD
symptoms (Mandell et al., 2007). When HCPs offer diagnostic and intervention care to families of
culturally diverse backgrounds based on knowledge and understanding of these cultural factors, there
exists a greater potential for reducing the gap of health care disparities for African American and
Hispanic children with ASD (Burkett and Morris, 2015, Zuckerman et al., 2014).

The Diagnostic Process
Early Identification of ASD
Identification of ASD as early as 18 to 24 months of age is imperative so HCPs can direct families of
children with ASD to evidence-based treatments for the best child and family outcomes (Weitlauf
et al., 2014). Multiple studies have shown the effectiveness of early and intensive treatments on child
outcomes in ASD (Dawson et al., 2010, Weitlauf et al., 2014). In response to this urgent need to
recognize the signs of ASD early in a child's life, the Centers for Disease Control and Prevention (CDC)
developed the “Learn the Signs Act Early” campaign, including a booklet listing normal child
developmental milestones (Daniel, Prue, Taylor, Thomas, & Scales, 2009). An element of the campaign
is the development and distribution of “Milestones booklets” that list the normal child developmental
milestones. These booklets are available as a free download on the CDC Web site
(http://www.cdc.gov/ncbddd/actearly/freematerials.html). To date, no research studies are available
in the medical literature with regard to the effectiveness of this campaign.
The CDC also provides training video clips of the key early indicators of a risk for ASD to assist clinicians
in the diagnostic process. The Learn the Signs Act Early Curriculum: Autism Case Training Videos
(http://www.cdc.gov/NCBDDD/video/actearlycurriculum/index.html) are illustrative and promote
understanding of the qualitative impairments of ASD, supplemented by the written text definitive
criteria for ASD as outlined in the DSM-5 manual.

Primary care screening
Primary care providers screen for ASDs for children 18 and 24 months of age based on American
Academy of Pediatrics (AAP) guidelines (Council on Children With Disabilities, 2006, Johnson and
Myers, 2007). Numerous screening tools specific to ASD symptoms are available (Council on Children
With Disabilities, 2006, Gardner, 2012, Zwaigenbaum, 2011). A commonly used tool is the Modified
Checklist for Autism in Toddlers Revised Form (Herlihy et al., 2014, Robins et al., 2014). Primary care
providers refer children for expert diagnostic evaluations if they appear to be at risk for ASD, based on
this preliminary screening tool. Box 2 lists absolute “red flags” that should prompt referral for further
diagnostic evaluation for ASD. These red flags are generally accepted by developmental specialists and
are consistent with the social communication and restricted and repetitive behavior hallmarks of ASD.
For children with positive ASD screening results and clinician concern, timely referral to both a
developmental clinic for further diagnostic evaluations and referral to community early intervention
program should occur simultaneously (Gardner, 2012, Johnson and Myers, 2007, Manning-Courtney
et al., 2013).
Box 2
Absolute indications for referral for autism spectrum disorder diagnostic evaluation
No babbling by 12 months
No gesturing (e.g., pointing and waving bye-bye) by 12 months
No single words by 16 months
No two-word spontaneous (not echolalic) phrases by 24 months
Any loss of any language or social skills at any age
Note. Data from Filipek et al., 2000, Gardner, 2012, Johnson and Myers, 2007.

Expert Diagnosis
No medical or diagnostic markers exist to definitively diagnose ASD. The diagnostic process by experts
involves comprehensive developmental screening by a multidisciplinary team of clinicians, including
ASD-specific screening, which has been shown to be more reliable in detecting ASD than clinician
observation alone (Daniels and Mandell, 2013, Guevara et al., 2013, Miller et al., 2011). The team
evaluation consists of a developmental pediatric evaluation, administration of an ASD-specific
diagnostic instrument, and a psychological evaluation. The developmental pediatric evaluation includes
a detailed family, birth, medical, and developmental history, physical and neurologic examination, and
developmental observations. The ASD-specific diagnostic instrument is the Autism Diagnostic
Observation Schedule (ADOS), which is a standardized instrument that assesses social and
communicative functions (Lord et al., 2012). Trained evaluators from any discipline such as speech and
language, psychology, nursing, and education can administer the ADOS. The ASD-specific psychology
evaluation includes standardized cognitive (intelligence quotient [IQ]), behavioral, emotional, and ASDspecific assessments.
Further medical evaluations are customized to the individual clinical situation. Because one early
indicator of ASD is the inability of a child to orient to his or her name (Schaefer & Mendelsohn, 2013),
all children should have an audiogram to rule out hearing loss as part of the effort to secure an
accurate diagnosis. Children with significant hearing loss may display socialization and communication

difficulties and be misidentified as having ASD (Schaefer & Mendelsohn, 2013). After an accurate
diagnosis, the primary care medical home provider should refer the child for genetics evaluation
because ASD is thought to have a genetic basis (Schaefer & Mendelsohn, 2013).

Genetic and Genomics of Autism
The underlying cause of ASD and the subsequent challenging behaviors of children with ASD is the
subject of much debate and research. It is commonly accepted that ASD is influenced by genetics
(Buxbaum et al., 2014, Johnson et al., 2013b; Myers et al., 2011, Veenstra-Vanderweele et al., 2004),
contributing factors in the environment (Shelton, Hertz-Picciotto, & Pessah, 2012), and maternal
immune-mediated responses (Lyall, Ashwood, Van de Water, & Hertz-Picciotto, 2014). Researchers are
studying several environmental factors that may affect gene expression and that also may modify gene
expression via epigenetic changes (Shulha et al., 2012).
An international consortium of researchers has progressed in our understanding of ASD genetics by the
use of candidate gene analysis, gene sequencing, and the study of copy number variants
(CNVs; Buxbaum et al., 2014). Current research supports a major genetic contribution in children
diagnosed with ASD in approximately 10% of children assessed by Fragile X testing and chromosome
microarray analysis (Buxbaum et al., 2014). Fragile X, a single gene disorder affecting intellectual
ability, is the most common single known cause of ASD (Kidd et al., 2014). Chromosome microarray
analysis is a test that detects deletion or duplications of stretches of deoxyribonucleic acid known as
CNVs. Chromosome microarray analysis is increasingly recommended in autism spectrum disorders
(Peters & Pertile, 2014). Ongoing research seeks to determine new genetic biomarkers that measure
the causes of ASD with more accuracy.
With the heterogeneity of ASD, it is difficult to tell how the genetic determinants affect socialization
and behavior directly. Various models attempt to understand the connection of the ASD genotype to
the phenotype. One model depicts ASD as a disturbance of physiological and behavioral rhythms that
possibly affect the child's development of social communication impairments and repetitive behaviors
and interests (Tordjman et al., 2015). For now, HCPs assess and treat the symptoms of the co-morbid
conditions rather than treating ASD as a singular disorder. The identification of an underlying genetic
disorder would help provide a unifying diagnosis for the child with ASD (Schaefer & Mendelsohn,
2013). Many syndromes have an established documented association with ASD (Johnson et al., 2013b,
Schaefer and Mendelsohn, 2013; see Table 1). For these syndromes, no further investigation of the
cause of the ASD is needed (Schaefer & Mendelsohn, 2013). There is no known cure for ASDs or
consensus regarding the most effective intervention strategy (Myers & Johnson, 2007). Evidence
suggests that only a minority of children progress to the point where they do not meet ASD diagnostic
criteria (Fein et al., 2013).
Table 1. Genetic disorders associated with autism spectrum disorder
Disorder

Incidence

Fragile X

1/3,600
males;

% Co-occurring
with ASD
15-30 (Harris,
2011)

Descriptions
Single gene disorder affecting intellectual
ability (Harris, 2011)

Rett syndrome

1/8,000
females
1/10,000
females

Tuberous sclerosis 1/6,000
Down syndrome

1/691

25-40 (Harris,
2011)
25-60 (Harris,
2011)
40 (Warner,
Moss, Smith, &
Howlin, 2014)

Regressive neurodevelopmental disorder of
speech and unusual hand movement (Neul
et al., 2010)
Nonmalignant tumors primarily in the brain,
eyes, and heart
Low muscle tone, small stature; more
behavior problems than children with Down
syndrome only (Warner, Moss, Smith, &
Howlin, 2014)

Note. ASD = autism spectrum disorder.
Data from Siegel & Beaulieu, 2012.

Interventions
Two systematic reviews of therapies for persons with ASD have been performed—one for children up
to 12 years old (Weitlauf et al., 2014) and one for children ages 12 to 18 years (Lounds Taylor et al.,
2012). Both reviews address areas for medical, educational, and behavioral interventions that may be
used as evidence for clinical guidelines. In the review for the children aged 12 to 18 years, only five
studies on medications were available, most of which were poor quality, pointing to a need for more
research for this age group (Lounds Taylor et al., 2012).
Families typically choose which interventions to use for their child (Karst & Van Hecke, 2012) but tend
to not have the time, resources, or expertise to consider all the options available (Stephenson, Carter,
& Kemp, 2012). The high cost and variability in public funding and insurance coverage for some ASD
interventions and complicated step-by-step formats of some interventions limit their feasibility and
accessibility. As a result, parents may choose diets or medications not proven to be effective simply
because they are straightforward interventions available at home (Lord & Bishop, 2010). Matson,
Adams, Williams, and Rieske (2013) report that there is low parental adherence and compliance to
medically prescribed treatments. In addition, parents may experience high levels of stress as a result of
the child's challenging behaviors. This stress takes a toll on the health of parents and may lead them to
delay seeking care for their child (Bekhet et al., 2012, Cantwell et al., 2014, Johnson et al., 2011,
Kerfeld et al., 2011, Lovell et al., 2012).
Recent literature highlights the importance of collaboration between parents and HCPs, known as
shared decision making (SDM), for treatment selection, rather than simply expecting parent and child
adherence to treatment recommendations (Institute of Medicine, 2015, Strauss et al., 2015, U.S.
Department of Health and Human Services, 2010). Caregivers of children with ASD report a lack of
SDM, difficulty accessing services, poor care coordination, and adverse family experiences compared
with caregivers of children with developmental disabilities, mental health conditions, or both (Carbone
et al., 2010, Vohra et al., 2014). Two inherent issues exist: limited SDM for ASD, and, even when SDM is
present, a lack of HCPs who understand the complexity of parenting a child with ASD (Bultas, 2012,
Johnson et al., 2011).

Medical and Related Interventions
Medical interventions target the symptoms of the developmental, psychiatric, neurologic, and
gastrointestinal disorders that may co-occur with ASD (Levy et al., 2010). After receiving the medical
diagnosis of ASD, children may be referred to specialists or an ASD center for ongoing developmental
and medical follow up of co-occurring conditions. The focus in follow-up medical visits can often be
problem-focused, reviewing with the family their day-to-day care of their child with ASD. As with many
other chronic medical conditions, other medical problems can be seen that require acute episodic
health care.
Seizures
Approximately 30% of children on the autism spectrum may have seizures sometime during their life
(Tuchman, Moshe, & Rapin, 2009). Andell and colleagues (2015) reported that the most common
neurodevelopment comorbidities of children 0 to 18 years (n = 766) who had a new-onset unprovoked
seizure were developmental delay (22%; confidence interval [CI], 19% to 25%), speech/language and
learning difficulties (23%; CI, 20% to 26%), and intellectual disability (16%; CI, 13% to 18%). Seizures
were more common in older children with co-occurring psychiatric diagnosis (Andell et al., 2015). The
onset of epilepsy peaks during adolescence and adulthood in ASD, for unknown reasons, and may be
unique to children with ASD compared with other developmental disabilities (Tuchman et al., 2009).
Gastrointestinal disturbances
Research on specific gastrointestinal disorders that co-occur with ASD is limited. Gastrointestinal
symptoms are difficult to evaluate because of the child's limited communication (Buie et al., 2010).
Problem behavior in children with ASD may be the primary or sole symptom of an underlying
gastrointestinal condition (Buie et al., 2010). Parents report that gastrointestinal issues are often the
antecedent to challenging child behaviors and dysregulated sleep (Coury, Ashwood, et al., 2012). These
conditions include gastroesophageal reflux disease, eosinophilic esophagitis, or and/or constipation
(Coury, Ashwood, et al., 2012). Sensory integration differences may result in textural aversions to
certain foods and a limited repertoire of food choices with a very selective diet (Badalyan and
Schwartz, 2012, Chandler et al., 2013). The altered eating habits, along with psychopharmacological
treatment, genetics, disordered sleep, and lack of adequate physical activity, contribute to the risk of
obesity in this population (Curtin, Jojic, & Bandini, 2014). Children with ASD have a higher prevalence
of obesity than the general population (Curtin, Anderson, Must, & Bandini, 2010).
Some parents of children with ASD try the gluten casein-free diet in an attempt to help improve their
child's behavior. The diet is an exclusion diet that is costly and inconvenient. Evidence is lacking that
following this diet improves a child's challenging behaviors and cognitive and social functioning
(Millward, Ferriter, Calver, & Connell-Jones, 2008). Furthermore, following a gluten casein-free diet
may place children at risk for suboptimal bone development (Geraghty, Depasquale, & Lane, 2010).
Pain sensitivity
In a systematic review of the pain of children with ASD, children with ASD were found to have different
patterns of pain and discomfort expression than typically developing children. Instead of crying and
seeking comfort, some children with ASD express pain differently (Allely, 2013). For example, some
children with ASD who are in pain display the following: “furrowed brow,” “banging his/her head,”
“injuring oneself,” “grimacing,” “guarding,” and “increased heart rate” (Inglese, 2008). Other identified

indicators of pain may be subjective and required (a) knowledge of the child's baseline and (b)
monitoring for changes from normal (i.e., “crankiness,” “being less active,” “rocking unusually,”
“acting,” “off,” and “irritability”; Inglese, 2008). HCPs must be careful to not interpret this lack of
typical finding as pain insensitivity or incorrectly assume that the child is in no pain (Allely, 2013). Close
collaboration with parents to learn how their child expresses pain is indicated because some parents
are able to describe unique behaviors that let them know when their child is in pain (Allely, 2013).

Medication Management of Symptoms of ASD
The use of medication in children with ASD is varied and usually symptom-specific. No medication has
yet been developed that targets the core deficits seen in ASD—specifically, disordered language and
social skill deficits. However, when concurrent medical symptoms are present, medications can be
useful. The use of medication is carefully reviewed in the context of current health status and ongoing
treatments. In determining a medication for behavior concerns, a careful history is needed to identify
what may be triggering symptoms. For example, if anxiety seems to precede behavior outbursts, then
anti-anxiety medication may be appropriate. The HCP should review with the family that the goal of
medication treatment is to lessen the intensity of a symptom that may be interfering with the child's
ability to make progress. Deciding to begin a medication is often a “try and see” or trial approach, with
a “start low and go slow” format for making dose adjustments (Reinhold & Manning-Courney, 2007).
Many children with ASD take psychotropic medications for challenging behaviors. In one study, Coury
and colleagues determined the percentage of children with ASD (n = 2,853 children ages 3 to 17 years)
who took at least one psychotropic medication by age range as follows: 11% of children aged 3 to
5 years; 46% of children aged 6 to 11 years; and 66% of children aged 12 to 17 years (Coury,
Anagnostou, et al., 2012). Thus more teenagers are medicated than are children. The number of
clinical trials of psychotropic medications continues to increase, which is helpful in guiding clinical
practice. Measuring outcomes in the use of these medications continues to be difficult. Additionally,
many medications in current use are considered “off-label,” without Food and Drug Administration
(FDA) approval. However, avoiding agents that are off-label limits choices for potentially efficacious
treatment. Currently, only two psychotropic medications, risperidone and aripiprazole, have FDA
approval in the treatment of children with aggression and ASD (Weitlauf et al., 2014). Overall,
medication combined with behavioral intervention appears to be more effective for reducing
aggressive behavior than medication alone (Dawson & Burner, 2011).
Many children with ASD take psychotropic medications for challenging behaviors.
Some children on the autism spectrum have significant inattention, distractibility, and/or hyperactive
behavior. Stimulant medications such as methylphenidate (Ritalin) diminish impulsivity and
hyperactivity by blocking the reuptake of catecholamine (norepinephrine and dopamine) at the
synaptic cleft (Purper-Ouakil, Ramoz, Lepagnol-Bestel, Gorwood, & Simonneau, 2011). Stimulants
improve focus and decrease aggression for children with and without ADHD (Blader et al., 2013).
Table 2 lists common problems and psychotropic medications used in the treatment of ASD.
Table 2. Co-occurring conditions, diagnostics, and medications for autism spectrum disorder
Problem

Comments

Medications

Anxiety and
obsessive
compulsive
features

Medications are not the first line of
SSRIs: citalopram, clomipramine,
treatment but may be helpful in
desipramine, fluoxetine, fluvoxamine,
lowering anxiety
paroxetine, and sertraline;
SSRI medications have not been
An alternate anxiolytic, buspirone, has
studied enough to know if they are
been used as an add-on medication or
helpful for ASD symptoms
an alternative to the SSRI category
SSRIs carry a black box warning
Benzodiazepines are used with
caution because of the possibility of
paradoxical effect and/or tolerance
Hyperactivity,
Stimulant medications have not
Stimulant: methylphenidate
distractibility,
been studied enough to know if they Amphetamine and
or inattention
are helpful for ASD symptoms
dextroamphetamine: Adderall
Atomoxetine cannot be crushed or
Alpha-2 agonist: clonidine, guanfacine
sprinkled and takes several weeks
for onset
Alpha 2 agonists (short and long
acting) have been used off label and
in younger children
Aggression,
Only two medications approved for
Antipsychotic agents: aripiprazole
agitation, selfthe treatment of agitation and
chlorpromazine, clozapine, haloperidol,
injurious behavior aggression in children with ASD:
olanzapine, perphenazine, risperidone,
risperidone and aripiprazole
and ziprasidone
Antipsychotics associated with
Mood stabilizer: carbamazepine,
weight gain, sleepiness, tremors and divalproex, lamotrigine, levetiracetam,
abnormal movements
lithium, and oxcarbazepine
Antiepileptic medications have been
used to stabilize mood
Seizures
1. EEG studies recommended for
Antiepileptic medications: lamotrigine,
staring with unresponsiveness
oxcarbazepine, valproate
2. Neuroimaging studies
recommended if EEG abnormalities
are present
Note. ASD = autism spectrum disorder; EEG = electroencephalogram; SSRI = selective serotonin
reuptake inhibitor.
Data from Siegel & Beaulieu, 2012.

Educational Intervention
The Individuals with Disabilities Education Improvement Act (IDEIA) mandates that parents of children
aged 3 to 21 years with ASD be actively involved in decisions about the services and accommodations
for their child through SDM (U.S. Department of Education, 2015). According to IDEIA, state
departments of instruction are mandated to identify students with ASD and provide services in special
education programs in the local school district for those older than 3 years. For children younger than
3 years, early intervention services are available throughout the United States, based in state county

programs (U.S. Department of Education, 2015). Some children may only be diagnosed with ASD as
part of a school evaluation rather than a formal evaluation for ASD. An educational diagnosis of ASD is
based on the criteria from IDEIA (IDEIA, 2004). This educational ASD diagnosis can be quite helpful in
guiding the child's individualized educational plan.
Early intervention services must be provided in natural environments, including the home and
community settings in which children without disabilities participate.
Early intervention services must be provided in natural environments, including the home and
community settings in which children without disabilities participate. Parents of children with ASD are
supported to help their children generalize skills learned at school into the home (Carter et al., 2013,
Machalicek et al., 2008). Children receive other therapeutic interventions at school, such as speech and
language therapy and occupational therapy for fine motor deficit and sensory integration difficulties
(Weitlauf et al., 2014).

Behavioral Interventions
Numerous interventions have been designed to target the core features of ASD—that is, social
communication and social interaction deficits and restricted, repetitive patterns of behavior, interests,
or activities (see Table 3). Applied behavior analysis (ABA) is considered a best practice for the
education of children with ASD, intellectual disability, and related disorders (Hagopian & Hardesty,
2015). ABA was first defined in 1968 as the process of systematically applying interventions based
upon the principles of learning theory directed at improving the behavior (Baer, Wolf, & Risley, 1968).
Table 3. Select interventions for autism spectrum disorder
Program
Early intensive
behavioral
intervention

Cognitive
behavioral therapy

Social skills
programs

Select examples
1. Applied behavior analysis (Lovaas, 1987)

Focus
Overall development

2. Early Start Denver (Dawson et al., 2010)

Overall development,
core symptoms, adaptive
behavior
Parent led, play based

3. Pivotal response training (Koegel, Koegel,
Harrower, & Carter, 1999)
4. Floor time therapy derived from the
Developmental Individual-Difference
Relationship–based model (Wieder & Greenspan,
2003)
1. Coping Cat (McNally Keehn, Lincoln, Brown, &
Chavira, 2013)
2. Facing your fears (Reaven, Blakeley-Smith,
Leuthe, Moody, & Hepburn, 2012)
1. Skill streaming (Goldstein & McGinnis, 1997)

Parent follows child's
lead

Helps high-functioning
children manage anxiety
Helps high-functioning
children manage anxiety
Social skills, attention,
play

2. Joint attention, symbolic play, engagement, and
regulation (JASPER; Kasari, Gulsrud, Paparella,
Hellemann, & Berry, 2015)

Parent mediated for joint
attention and
cooperative play

ABA uses a behaviorist approach for either comprehensive or focused interventions (Hagopian &
Hardesty, 2015). Comprehensive interventions aim to improve skills that have an impact on global
measures of functioning over time, such as IQ, language/communication, socialization, discrimination,
and attention (Hagopian & Hardesty, 2015). Small amounts of information are presented in repeated
trials, using clear interactions, which are structured in a three-part contingency pattern (antecedentresponse-consequence; Weitlauf et al., 2014). Comprehensive ABA is generally home based for 25 to
40 hours/week for several years (Hagopian & Hardesty, 2015). By contrast, focused interventions occur
over a shorter amount of time. For example, a functional behavioral assessment to identify the
variables antecedent to a problem behavior, such as aggression or self-injury, is considered a focused
intervention (Hagopian & Hardesty, 2015).
Scientific support during the past 40 years links ABA-based procedures with reduction of problem
behaviors and increasing appropriate skills (Hagopian & Hardesty, 2015). Research on children who
received comprehensive ABA therapy for at least 8 months to 2 years showed greater improvements in
cognitive performance, language skills, and adaptive behavior skills than broadly defined eclectic
treatments available in the community (Weitlauf et al., 2014). A subset of all children who receive early
intensive intervention showed significant improvement in terms of standardized outcomes, although
many children continue to have substantial problems (Weitlauf et al., 2014). Research also shows
promise for Naturalistic Developmental Behavioral Interventions (Schreibman et al., 2015), which use
the principles of ABA in settings that are naturalistic, such as home and with a different arrangement of
the three-part contingency. For example, a child may be placed in an environment (e.g., the kitchen)
where he or she has to initiate an interaction with someone (e.g., ask for an apple) to get a desired
item (apple) (Schreibman et al., 2015).
Some evidence suggests that improvements with ABA may vary with the underlying severity of the
disorder, but more research for the correlates of improvement is needed (Weitlauf et al., 2014). Future
research needs to look at how family functioning affects outcomes of ABA therapy and include
measures of parental well-being (Howlin, Magiati, & Charman, 2009). Because family functioning
affects child behaviors, all children who receive ABA therapy may not have acquired adequate adaptive
behavior skills to cope with stressful acute episodic health care interactions. In an effort to help with
family functioning, Autism Speaks has created tool kits with evidence-based guidance for parents with
children with challenging behaviors (Autism Speaks, 2012) and ABA therapy (Autism Speaks, 2015).
More information on the behavior management of children with ASD can be found in part 2 of this
two-part publication on translating evidence to practice for children with ASD.

Conclusion
The research base representing the translation of evidence to practice for the health care of children
with ASD is still a developing area of research. We presented background on the current state of the
science related to ASD definition, associated behaviors, prevalence, diagnostic process, and

interventions. This evidence can inform health care institution clinical guidelines and policies. Future
research is needed to test interventions that decrease children's challenging behaviors and promote
SDM among HCPs and families to optimize child and family health outcomes in health care settings.
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